Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab in previously treated advanced melanoma and renal cell carcinoma
ChiCTR2400090453Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab in melanoma and renal cell carcinoma (RCC) (4 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Objective response rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2400090453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090453.